Researchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

Based on offerings, the genomics market is divided into product and service segments. The product segment accounted for the largest share of the genomics market in 2023. This dominance is primarily ...

Genes contain instructions for making proteins, and a central dogma of biology is that this information flows from DNA to RNA ...

CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...

HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company, announced that the U.S. FDA has cleared its investigational new drug (IND) application for HG202, the world's first ...

CRISPR Technology Market CRISPR Technology Market Dublin, Oct. 31, 2024 (GLOBE NEWSWIRE) -- The "CRISPR Technology Market" report has been added to ResearchAndMarkets.com's offering.The CRISPR ...

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...

NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated protein 9. NTLA-2002 targets the gene encoding ...

Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, linking its hereditary angioedema (HAE) prospect to an 81% reduction in ...

Labroots invites you to the 7th Annual Event in the CRISPR Virtual Event Series 2024 taking place on October 23rd, 2024! This event will continue the conversation of the abilities of CRISPR-based ...